Promising data for Sanofi, Regeneron’s dupilumab
admin 17th October 2017 Uncategorised 0Sanofi and Regeneron have unveiled positive results from a mid-stage study exploring the potential of the biologic dupilumab in adults with eosinophilic esophagitis, and also signed a deal with Aimmune Therapeutics to test an experimental peanut allergy therapy.
More: Promising data for Sanofi, Regeneron’s dupilumab
Source: News